Actively Recruiting

Phase 4
Age: 18Years - 75Years
All Genders
NCT06691191

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

Led by University of Florida · Updated on 2026-02-05

48

Participants Needed

1

Research Sites

103 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Ticagrelor currently represents the most tested and commonly used P2Y12 inhibitor monotherapy following percutaneous coronary intervention. The purpose of this study is to conduct a head-to-head comparison on the pharmacodynamic efficacy of ticagrelor-based and prasugrel-based single antiplatelet therapy. To determine if the PD profiles of ticagrelor- and prasugrel-based SAPT are comparable, we aim to conduct a non-inferiority study between the two strategies.

CONDITIONS

Official Title

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients on dual antiplatelet therapy with aspirin plus prasugrel 10 mg or ticagrelor 90 mg twice daily for at least 90 days after PCI
  • Age between 18 and 75 years old
  • Able to provide written informed consent
Not Eligible

You will not qualify if you...

  • History of stent thrombosis
  • PCI within the last 90 days
  • History of stroke or transient ischemic attack (TIA)
  • Age over 75 years old
  • Weight less than 60 kg
  • History of intracranial hemorrhage
  • Current treatment with oral anticoagulants or chronic low-molecular-weight heparin for venous thrombosis
  • Known coagulation disorders
  • Severe liver impairment
  • Allergic reaction to prasugrel or ticagrelor
  • Pregnant or breastfeeding; persons of childbearing potential must use reliable birth control and will have pregnancy testing prior to participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Florida Jacksonville

Jacksonville, Florida, United States, 32209

Actively Recruiting

Loading map...

Research Team

F

Francesco Franchi, MD

CONTACT

A

Andrea Burton

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here